Unicycive Therapeutics Inc. (NASDAQ: UNCY) is 309.26% higher on its value in year-to-date trading and has touched a low of $0.40 and a high of $2.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The UNCY stock was last observed hovering at around $2.17 in the last trading session, with the day’s gains setting it 0.04% off its average median price target of $7.00 for the next 12 months. It is also 83.0% off the consensus price target high of $13.00 offered by 4 analysts, but current levels are 55.8% higher than the price target low of $5.00 for the same period.
Currently trading at $2.21, the stock is 139.44% and 220.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.72 million and changing 1.84% at the moment leaves the stock 202.31% off its SMA200. UNCY registered 68.70% gain for a year compared to 6-month loss of 204.83%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a 301.82% gain in the last 1 month and extending the period to 3 months gives it a 195.49%, and is 47.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 32.21% over the week and 18.36% over the month.
Unicycive Therapeutics Inc. (UNCY) has around 9 employees, a market worth around $25.64M and $1.00M in sales. Distance from 52-week low is 451.95% and -23.00% from its 52-week high.
Unicycive Therapeutics Inc. (UNCY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Unicycive Therapeutics Inc. (UNCY) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Unicycive Therapeutics Inc. is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -327.70% this year.
Unicycive Therapeutics Inc. (UNCY) Top Institutional Holders
The shares outstanding are 15.06M, and float is at 8.84M with Short Float at 1.67%.
Unicycive Therapeutics Inc. (UNCY) Insider Activity
A total of 0 insider transactions have happened at Unicycive Therapeutics Inc. (UNCY) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Schiller Brigitte,the company’sDirector. SEC filings show that Schiller Brigitte bought 15,000 shares of the company’s common stock on May 16 at a price of $0.82 per share for a total of $12375.0. Following the purchase, the insider now owns 15000.0 shares.
